Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) Sees Large Decline in Short Interest

Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) was the recipient of a significant drop in short interest in July. As of July 15th, there was short interest totaling 51,582 shares, a drop of 38.4% from the June 30th total of 83,765 shares. Currently, 5.2% of the company’s stock are short sold. Based on an average trading volume of 36,650 shares, the days-to-cover ratio is presently 1.4 days.

Virtus LifeSci Biotech Clinical Trials ETF Trading Up 3.8%

NYSEARCA BBC traded up $1.84 on Thursday, hitting $50.27. 13,780 shares of the stock were exchanged, compared to its average volume of 24,128. Virtus LifeSci Biotech Clinical Trials ETF has a fifty-two week low of $20.87 and a fifty-two week high of $54.95. The company has a 50-day moving average price of $47.55 and a 200-day moving average price of $44.19.

Hedge Funds Weigh In On Virtus LifeSci Biotech Clinical Trials ETF

An institutional investor recently bought a new position in Virtus LifeSci Biotech Clinical Trials ETF stock. Worth Asset Management LLC purchased a new stake in Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,093 shares of the company’s stock, valued at approximately $216,000. Worth Asset Management LLC owned approximately 0.41% of Virtus LifeSci Biotech Clinical Trials ETF at the end of the most recent reporting period.

Virtus LifeSci Biotech Clinical Trials ETF Company Profile

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.